Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
https://link.springer.com/article/10.1007/s10875-023-01452-4
You may remember him from his previous hits such as...
"William Fischer, M.D., University of North Carolina (UNC), a lead investigator of SNG001 said: "These results, including a decrease in hospitalisations and adverse events among participants who received SNG001, are promising and warrant further investigation in a larger Phase 3 clinical trial. SNG001 is the first nebulized inhaled therapeutic to demonstrate promising results and, if confirmed in larger studies, could represent a potential treatment option for people who have COVID-19 but are not hospitalised."
https://twitter.com/Synairgenplc/status/1628003313764470786?t=KbPEuiCZbl4o19_MWYM_yA&s=19
For #media #attendees #investors
Meet us today in #Seattle at #CROI2023 & join #SNG CSO @PhillMonk for @WFischerII presentation on Safety and Efficacy of Inhaled Interferon-B1a in Outpatients with COVID-19 data from ACTIV-2 Phase 2 trial at 10:29 am Pacific Time #antivirals
Great point regarding prophylactic use of interferon Andy, thumbs up champ.
(Wonder what it is about this thread that's got him pulling out all the old one liners trying to start a fight and get it removed?) Hmmmm.
The prophylactic effect of inf is well documented. With published studies as far back as the 60s documenting efficacy at preventing disease. However the major stumbling block had always been the associated side effects of systematic or simple nasal spray applications. Given the now proven safety record of inhaled INFb, it would be right and correct to study it's potential as a prophylactic and/or a post exposure treatment.